Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report

Harrer DC, Menhart K, Mayer S, Herr W, Reichle A, Vogelhuber M (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Frontiers in Oncology Frontiers Media

Book Volume: 10

Article Number: 585830

DOI: 10.3389/fonc.2020.585830

Abstract

Anaplastic large cell lymphoma (ALCL) with ALK-translocation constitutes an aggressive lymphoma with high sensitivity to anthracycline-based chemotherapy. Relapse, however, is observed in about one-third of patients. Salvage treatment incorporates high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, treatment with the CD30-specific immunoconjugate Brentuximab vedotin (BV) and the use of ALK-inhibitors, such as crizotinib. In this case report, we present a patient with a rare late relapse of ALK-positive ALCL following chemotherapy, who was neither eligible for high-dose chemotherapy nor treatment with BV. Relapse therapy was carried out with daily crizotinib, which rapidly mediated complete regression of all ALCL manifestations. In light of few clinical trials published on the use of crizotinib against ALCL, we want to further substantiate the efficacy of crizotinib as salvage therapy in patients with relapsed ALCL especially if ineligible for high-dose chemotherapy or BV treatment. Finally, we would like to enhance vigilance for potential late relapse of ALCL more than a decade after frontline treatment.

Involved external institutions

Universitätsklinikum Regensburg DE Germany (DE)

How to cite

APA:

Harrer, D.C., Menhart, K., Mayer, S., Herr, W., Reichle, A., & Vogelhuber, M. (2020). Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.585830

MLA:

Harrer, Dennis Christoph, et al. "Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report." Frontiers in Oncology 10 (2020).

BibTeX: Download